Kymera Therapeutics KYMR Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's additional paid-in capital?
- Kymera Therapeutics (KYMR) reported additional paid-in capital of $2.68B in Q1 2026.
- How has Kymera Therapeutics's additional paid-in capital changed year-over-year?
- Kymera Therapeutics's additional paid-in capital increased by 66.8% year-over-year, from $1.61B to $2.68B.
- What is the long-term trend for Kymera Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Kymera Therapeutics's additional paid-in capital has grown at a 45.0% compound annual growth rate (CAGR), from $412.78M to $2.64B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.